SETX

Across TCGA pan-cancer cohorts, SETX mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SETX data layer compared with 22 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SETX mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SETX expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where SETX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.970	0.832	.002	12	view →
PDAC	OS	Median	III,IV	1.000	0.537	.008	9	view →
UCEC	DFS	Median	All	0.851	0.952	.017	4	view →
GBM	OS	Median	All	0.567	0.239	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SETX–LUAD (DFS)

Open the LUAD breakdown →